A Multicentre, Intra-patient Randomised Controlled Phase III Study to Confirm the Efficacy and Safety of denovoSkin™, a Bilayer Engineered Collagen-based Skin Graft Composed of Autologous Fibroblasts and Keratinocytes, for the Treatment of Patients With Deep Partial and Full-thickness Burns
Latest Information Update: 20 Aug 2026
At a glance
- Drugs EHSG-KF (Primary)
- Indications Burns
- Focus Registrational; Therapeutic Use
- Sponsors CUTISS
Most Recent Events
- 10 Aug 2026 Planned End Date changed from 30 Jun 2028 to 30 Jun 2029.
- 10 Aug 2026 Planned primary completion date changed from 31 Dec 2026 to 30 Jun 2027.
- 04 Jun 2026 This trial has been completed in Portugal and Belgium, according to Clinical Trials Information System.